Enzymotec Company Profile (NASDAQ:ENZY)

About Enzymotec (NASDAQ:ENZY)

Enzymotec logoEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Commodity Chemicals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ENZY
  • CUSIP: N/A
  • Web: www.enzymotec.com
Capitalization:
  • Market Cap: $263.34 million
  • Outstanding Shares: 22,949,000
Average Prices:
  • 50 Day Moving Avg: $10.87
  • 200 Day Moving Avg: $8.95
  • 52 Week Range: $5.20 - $12.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 51.14
  • P/E Growth: 4.66
Sales & Book Value:
  • Annual Revenue: $47.01 million
  • Price / Sales: 5.49
  • Book Value: $5.90 per share
  • Price / Book: 1.91
Profitability:
  • EBIDTA: ($4,560,000.00)
  • Net Margins: -14.52%
  • Return on Equity: -3.88%
  • Return on Assets: -3.58%
Debt:
  • Current Ratio: 6.85%
  • Quick Ratio: 4.72%
Misc:
  • Average Volume: 81,966 shs.
  • Beta: 1.24
  • Short Ratio: 1.26
 

Frequently Asked Questions for Enzymotec (NASDAQ:ENZY)

What is Enzymotec's stock symbol?

Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."

How were Enzymotec's earnings last quarter?

Enzymotec Ltd. (NASDAQ:ENZY) released its earnings results on Wednesday, August, 16th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.05 by $0.15. The business had revenue of $13 million for the quarter, compared to analysts' expectations of $12.78 million. Enzymotec had a negative net margin of 14.52% and a negative return on equity of 3.88%. The business's quarterly revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.04 earnings per share. View Enzymotec's Earnings History.

When will Enzymotec make its next earnings announcement?

Enzymotec is scheduled to release their next quarterly earnings announcement on Wednesday, November, 15th 2017. View Earnings Estimates for Enzymotec.

Where is Enzymotec's stock going? Where will Enzymotec's stock price be in 2017?

2 brokerages have issued 1-year price targets for Enzymotec's stock. Their predictions range from $8.00 to $8.00. On average, they expect Enzymotec's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Enzymotec.

What are analysts saying about Enzymotec stock?

Here are some recent quotes from research analysts about Enzymotec stock:

  • 1. According to Zacks Investment Research, "Enzymotec, Ltd. provides specialty lipid-based products and solutions. The Company develops, manufactures and markets bio-functional lipid ingredients as well as final products. It serves pharmaceuticals and nutrition industries worldwide. Enzymotec, Ltd. is based in Migdal HaEmeq, Israel. " (5/22/2017)
  • 2. Jefferies Group LLC analysts commented, "Enzymotec has been pressured by a shifting regulatory environment and lackluster demand even as it has accelerated investment in Vaya. Regulatory changes will continue to ripple through the supply chain in 2H17-2018. We expect shares to remain range-bound absent an improvement in end markets and sustained profitability in Vaya. Clarity around strategic opportunities in InFat and the pending CEO transition would help reduce its risk profile." (2/23/2017)

Who are some of Enzymotec's key competitors?

Who are Enzymotec's key executives?

Enzymotec's management team includes the folowing people:

  • Steve Dubin, Independent Chairman of the Board
  • Erez Israeli, President, Chief Executive Officer
  • Yoav Doppelt, Independent Vice Chairman of the Board
  • Dror Israel, Chief Financial Officer, Vice President
  • Yoav Kahane, Chairman of Advanced Lipids AB
  • Yoni Twito, Chief Operating Officer
  • Naama Zamir, Vice President - Human Resources and Information Systems
  • Gai Ben-Dror, Vice President - Process Development
  • Tzafra Cohen, Vice President - Research & Development
  • Tamar D. Howson, Director

Who owns Enzymotec stock?

Enzymotec's stock is owned by a number of of institutional and retail investors. Top institutional investors include FRUTAROM LTD (19.13%), FRUTAROM LTD (19.13%), GALAM LTD. (14.00%), FRUTAROM LTD (9.63%), BERESHEIT GENERAL PARTNER LTD. (6.10%) and Janus Henderson Group PLC (1.27%). View Institutional Ownership Trends for Enzymotec.

Who sold Enzymotec stock? Who is selling Enzymotec stock?

Enzymotec's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Laurion Capital Management LP, Menta Capital LLC, Public Employees Retirement System of Ohio and State of New Jersey Common Pension Fund D. View Insider Buying and Selling for Enzymotec.

Who bought Enzymotec stock? Who is buying Enzymotec stock?

Enzymotec's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC and State Street Corp. View Insider Buying and Selling for Enzymotec.

How do I buy Enzymotec stock?

Shares of Enzymotec can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzymotec's stock price today?

One share of Enzymotec stock can currently be purchased for approximately $11.25.


MarketBeat Community Rating for Enzymotec (NASDAQ ENZY)
Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  84 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  210
MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enzymotec (NASDAQ:ENZY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $8.00 (28.89% downside)

Analysts' Ratings History for Enzymotec (NASDAQ:ENZY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2017Jefferies Group LLCReiterated RatingHold$8.00N/AView Rating Details
11/17/2016Wells Fargo & CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
4/17/2016Canaccord GenuityReiterated RatingHoldN/AView Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Enzymotec (NASDAQ:ENZY)
Earnings by Quarter for Enzymotec (NASDAQ:ENZY)
Earnings History by Quarter for Enzymotec (NASDAQ ENZY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017$0.10N/AView Earnings Details
8/16/20176/30/2017$0.05($0.10)$12.78 million$13.00 millionViewN/AView Earnings Details
5/17/20173/31/2017$0.06$0.03$14.23 million$12.00 millionViewN/AView Earnings Details
2/22/2017Q416$0.03($0.10)$11.47 million$10.60 millionViewN/AView Earnings Details
11/16/2016Q316$0.07$0.03$13.29 million$11.40 millionViewN/AView Earnings Details
8/9/2016Q216$0.08$0.04$14.90 million$15.00 millionViewN/AView Earnings Details
5/19/2016Q116$0.05$0.09$13.85 million$14.00 millionViewListenView Earnings Details
2/17/2016Q415$0.10$0.07$14.01 million$13.30 millionViewListenView Earnings Details
11/11/2015Q315$0.07$0.08$14.21 million$12.40 millionViewListenView Earnings Details
8/12/2015Q215$0.06$0.11$12.39 million$13.40 millionViewListenView Earnings Details
5/7/2015Q115$0.06$0.09$12.10 million$12.25 millionViewN/AView Earnings Details
2/18/2015Q414$0.08$0.06$11.11 million$10.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.04$0.05$10.22 million$9.50 millionViewN/AView Earnings Details
8/5/2014Q214$0.10$0.02$14.88 million$11.50 millionViewN/AView Earnings Details
5/14/2014Q114$0.17$0.24$19.40 million$23.70 millionViewN/AView Earnings Details
2/13/2014Q413$0.11$0.15$11.64 million$18.51 millionViewN/AView Earnings Details
11/11/2013Q313$0.11$0.13$13.10 million$22.50 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzymotec (NASDAQ:ENZY)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171$0.00$0.00$0.00
Q3 20171$0.04$0.04$0.04
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Enzymotec (NASDAQ:ENZY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzymotec (NASDAQ:ENZY)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Enzymotec (NASDAQ:ENZY)
Latest Headlines for Enzymotec (NASDAQ:ENZY)
Source:
DateHeadline
americanbankingnews.com logoEnzymotec (ENZY) vs. Its Competitors Critical Contrast
www.americanbankingnews.com - September 16 at 12:10 AM
americanbankingnews.com logoCritical Comparison: Enzymotec (ENZY) vs. Innophos Holdings (IPHS)
www.americanbankingnews.com - September 11 at 8:54 AM
americanbankingnews.com logoHead to Head Survey: NewMarket Corporation (NEU) and Enzymotec (ENZY)
www.americanbankingnews.com - September 9 at 10:24 AM
americanbankingnews.com logoHead-To-Head Contrast: Enzymotec (ENZY) & Albemarle Corporation (ALB)
www.americanbankingnews.com - September 1 at 9:10 AM
streetinsider.com logoEnzymotec (ENZY) Reports Acquisition of Five Nurtritional Supplements from Union Springs Healthcare LLC
www.streetinsider.com - August 30 at 7:34 PM
finance.yahoo.com logoEnzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare
finance.yahoo.com - August 30 at 7:34 PM
americanbankingnews.com logoEnzymotec (ENZY) & Eastman Chemical (EMN) Head-To-Head Analysis
www.americanbankingnews.com - August 30 at 6:28 AM
reuters.com logoBRIEF-Enzymotec Ltd responds to unsolicited proposal from Frutarom Ltd
www.reuters.com - August 28 at 11:07 PM
nasdaq.com logoEnzymotec Advises Shareholders To Defer Decision On Frutarom's Proposal
www.nasdaq.com - August 28 at 11:07 PM
streetinsider.com logoEnzymotec (ENZY) Comments on Unsolicited Proposal from Frutarom
www.streetinsider.com - August 28 at 11:07 PM
finance.yahoo.com logoCorporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives
finance.yahoo.com - August 28 at 6:05 PM
finance.yahoo.com logoEnzymotec Ltd. Responds to Unsolicited Proposal from Frutarom Ltd.
finance.yahoo.com - August 28 at 6:05 PM
americanbankingnews.com logoBrokerages Expect Enzymotec Ltd. (ENZY) to Post $0.10 Earnings Per Share
www.americanbankingnews.com - August 25 at 4:50 PM
finance.yahoo.com logoFrutarom Bought a 9.2% Stake From Paulson, Enzymotec’s Largest Shareholder, to Reach a 19.1% Stake in Enzymotec
finance.yahoo.com - August 24 at 3:42 AM
americanbankingnews.com logoJefferies Group Analysts Boost Earnings Estimates for Enzymotec Ltd. (ENZY)
www.americanbankingnews.com - August 21 at 3:38 AM
reuters.com logoBRIEF-Enzymotec Ltd Q2 loss per share $0.10
www.reuters.com - August 17 at 7:38 PM
finance.yahoo.com logoEnzymotec Ltd. Reports Second Quarter 2017 Unaudited Financial Results
finance.yahoo.com - August 16 at 4:01 PM
finance.yahoo.com logoEnzymotec reports 2Q loss
finance.yahoo.com - August 16 at 4:01 PM
americanbankingnews.com logoEnzymotec Ltd. (ENZY) Announces Quarterly Earnings Results, Misses Estimates By $0.15 EPS
www.americanbankingnews.com - August 16 at 10:38 AM
americanbankingnews.com logoEnzymotec Ltd. (NASDAQ:ENZY) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - August 12 at 8:20 PM
americanbankingnews.com logoEnzymotec Ltd. (NASDAQ:ENZY) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 9 at 7:18 AM
americanbankingnews.com logoQuaker Chemical Corporation (KWR) & Enzymotec (ENZY) Head to Head Contrast
www.americanbankingnews.com - August 8 at 10:18 PM
reuters.com logoBRIEF-Frutarom reports 9.63 pct stake in Enzymotec ltd ‍ as of August 1
www.reuters.com - August 5 at 10:32 PM
reuters.com logoBRIEF-Frutarom reports 7.57 pct stake in Enzymotec
www.reuters.com - July 31 at 11:05 PM
streetinsider.com logoEnzymotec (ENZY) Announces Appointment of Dror Israel as CFO
www.streetinsider.com - July 29 at 10:30 PM
reuters.com logoBRIEF-Enzymotec Ltd appoints Dror Israel as CFO
www.reuters.com - July 29 at 10:30 PM
finance.yahoo.com logoEnzymotec to Report Second Quarter 2017 Financial Results
finance.yahoo.com - July 26 at 6:55 PM
reuters.com logoBRIEF-Beresheit General Partner reports 6.1 pct passive stake in Enzymotec
www.reuters.com - July 18 at 5:20 AM
reuters.com logoBRIEF-Enzymotec CFO to step down
www.reuters.com - June 29 at 4:01 AM
streetinsider.com logoForm 6-K Enzymotec Ltd. For: Jun 28
www.streetinsider.com - June 29 at 4:01 AM
finance.yahoo.com logoEnzymotec Chief Financial Officer to Step Down
finance.yahoo.com - June 28 at 6:00 PM
americanbankingnews.com logoJefferies Group Comments on Enzymotec Ltd.'s Q3 2017 Earnings (ENZY)
www.americanbankingnews.com - June 23 at 8:50 AM
americanbankingnews.com logoJefferies Group Weighs in on Enzymotec Ltd.'s Q2 2017 Earnings (ENZY)
www.americanbankingnews.com - June 22 at 7:38 AM
finance.yahoo.com logoEnzymotec Ltd. :ENZY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017
finance.yahoo.com - June 14 at 6:09 PM
finance.yahoo.com logoWeakness Seen in Enzymotec (ENZY) Estimates: Should You Stay Away?
finance.yahoo.com - June 13 at 12:01 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Sees Significant Drop in Short Interest
www.americanbankingnews.com - June 11 at 7:32 AM
finance.yahoo.com logoEnzymotec Launches Next Generation Krill Oil Product - K•REAL® Gold
finance.yahoo.com - June 6 at 5:24 PM
finance.yahoo.com logoEnzymotec Ltd. to Present at the Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 25 at 6:59 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - May 22 at 7:34 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Releases Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 20 at 12:32 AM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 19 at 9:46 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 19 at 2:26 PM
americanbankingnews.com logoEnzymotec Ltd (ENZY) Posts Earnings Results, Misses Expectations By $0.03 EPS
www.americanbankingnews.com - May 18 at 8:12 AM
finance.yahoo.com logoInvestor Network: Enzymotec Ltd. to Host Earnings Call
finance.yahoo.com - May 17 at 10:56 AM
finance.yahoo.com logoEnzymotec Ltd. Reports First Quarter 2017 Unaudited Financial Results
finance.yahoo.com - May 17 at 10:56 AM
finance.yahoo.com logoEnzymotec misses 1Q profit forecasts
finance.yahoo.com - May 17 at 10:56 AM
americanbankingnews.com logoZacks: Enzymotec Ltd (ENZY) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 12 at 2:38 PM
americanbankingnews.com logoEnzymotec (ENZY) Getting Positive Media Coverage, Report Finds
www.americanbankingnews.com - May 3 at 3:50 PM
finance.yahoo.com logoEnzymotec to Report First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 8:53 AM
finance.yahoo.com logoVAYA Pharma Introduces New Three-Month Supply of Vayarin® and Vayacog® Medical Foods
finance.yahoo.com - May 2 at 7:27 PM

Social

Chart

Enzymotec (ENZY) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by MarketBeat.com Staff